ArticleBJUI compass2026
The utility of PSA density for selection of targeted versus systematic transperineal prostate biopsy: A retrospective cohort study.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The objective of this study is to evaluate PSA density (PSAD) as an adjunctive predictor of prostate cancer (PCa) detection on magnetic resonance imaging (MRI)-guided transperineal biopsy and to identify PSAD thresholds across which systematic sampling may be safely omitted. Methods: Data were collected from men who underwent MRI-ultrasound software-assisted fusion transperineal biopsy from July 2023 to August 2025. The cancer detection rate of targeted, systematic and combined strategies was stratified by PSAD. Multivariable logistic regression was used to identify predictors of grade group (GG) ≥ 2 and GG ≥ 3 PCa. Results: Among 379 men undergoing biopsy, overall GG ≥ 2 detection increased with PSAD: 29.2% (<0.1), 42.7% (0.1-0.1499), 61.2% (0.15-0.1999) and 78.4% (≥0.2). On multivariable analysis, PSAD was associated with higher odds of GG ≥ 2 (OR 2.4, 95% CI 1.73-3.3, Conclusion: PSAD is an accessible metric that may guide risk stratification and biopsy strategy selection. A PSAD threshold of 0.2 may identify those in whom systematic sampling increases detection of low-grade disease with limited incremental yield for clinically significant disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.